Insmed unveils four new research platforms; targets 6 INDs by 2025; DMD gene therapy trial in 2023

INSMED Inc

Gene therapy with targeted AAV delivery; DMD clinical trial to start 2023, muscle biopsy data expected H1 2024.
RNA end-joining (REJ) technology targets Stargardt disease; IND submission expected by end of 2024.
Protein deimmunization platform (DbD) using AI to enable redosable gene therapy and therapeutic proteins.
Proprietary algae-based manufacturing platform for AAV capsid production; $500K investment from CureDuchenne Ventures.
Expects at least six IND applications across platforms by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.